Supreme Court Should Pass On Zarxio, Wait For Another Biosimilar Suit, Amgen Says

Sandoz's petition challenging biosimilar launch notification requirements isn't urgent, Amgen argues, but if court takes up case, Amgen also wants it to rule on whether patent dance is optional.